Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Should you sell your Eupraxia Pharmaceuticals stock? | 1 | Cantech Letter | ||
Mi | Eupraxia Pharmaceuticals Inc: Eupraxia releases first set of Resolve clinical results | 18 | Stockwatch | ||
Di | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
15.08. | Is Eupraxia Pharmaceuticals a buy? | 1 | Cantech Letter | ||
13.08. | Eupraxia Pharmaceuticals Inc: Eupraxia's June 30 cash balance at $19.8-million (U.S.) | 1 | Stockwatch | ||
12.08. | Eupraxia Pharmaceuticals reports Q2 results | 3 | Seeking Alpha | ||
12.08. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | 148 | GlobeNewswire (Europe) | Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026Announced positive data from Phase 1b/2a RESOLVE supporting... ► Artikel lesen | |
22.07. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
08.07. | Eupraxia Pharmaceuticals Inc: Eupraxia doses first patient in phase 2b Resolve trial | 1 | Stockwatch | ||
08.07. | Stocks in Play: Eupraxia Pharmaceuticals Inc. | - | Baystreet.ca | ||
08.07. | Eupraxia Pharmaceuticals Inc.: Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis | 68 | GlobeNewswire (Europe) | Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study to a Phase 2b placebo-controlled study. This is a critical step required... ► Artikel lesen | |
08.07. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
16.06. | Canaccord Genuity initiates Eupraxia stock with spec. buy on EoE treatment | 2 | Investing.com | ||
03.06. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders | 92 | GlobeNewswire (Europe) | VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
07.05. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 | 1 | GlobeNewswire (USA) | ||
07.05. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results | 156 | GlobeNewswire (Europe) | Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to... ► Artikel lesen | |
05.05. | Eupraxia Pharmaceuticals Inc: Eupraxia talks treatment outcomes in phase 1b/2a trial | 2 | Stockwatch | ||
05.05. | Stocks in Play: Eupraxia Pharmaceuticals Inc. | - | Baystreet.ca | ||
05.05. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
24.04. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,05 | +0,05 % | BioNTech: Chancen in Onkologie, Sorgen im Kurs | Die Aktie von BioNTech SE notiert aktuell bei 94,73 EUR. Nach dem beispiellosen Erfolg mit dem COVID-19-Impfstoff steht das Mainzer Biotech-Unternehmen vor der Herausforderung, seine Pipeline in Onkologie... ► Artikel lesen | |
QIAGEN | 40,390 | +0,44 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
NUVALENT | 80,89 | +1,53 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
DYNE THERAPEUTICS | 14,220 | +7,40 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
EVOTEC | 5,856 | +2,70 % | Evotec-Aktie: Ist das ein wichtiges Signal? | Die Evotec-Aktie bewegt sich weiterhin auf einem sehr niedrigen Niveau; am Montag verbessert sie sich aktuell um +1,5% und steht bei rund 6,10 €. Was bei dem deutschen Biotech-Unternehmen fehlt, sind... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,610 | +1,99 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 50,38 | +3,81 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
BEAM THERAPEUTICS | 20,890 | +12,68 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 25,980 | +9,16 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress | ||
MINERALYS THERAPEUTICS | 34,750 | +4,92 % | Mineralys reports positive subgroup data for hypertension drug | ||
VERA THERAPEUTICS | 24,220 | +10,59 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
CG ONCOLOGY | 33,105 | +7,00 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 59,42 | -0,50 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
ARS PHARMACEUTICALS | 10,090 | -5,61 % | Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential | ||
ARCUTIS BIOTHERAPEUTICS | 17,200 | +6,11 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen |